Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fanconi anemia group B protein (FANCB) is a core component of the Fanconi anemia (FA) DNA repair pathway, involved in repairing DNA interstrand crosslinks during DNA replication[2][3]. FANCB forms a central part of the FA core complex, assembling with FAAP100 and FANCL to create the catalytic E3 ubiquitin ligase subcomplex critical for the monoubiquitination of FANCD2 and FANCI[1][2]. This modification is essential for recruiting downstream nucleases and repair proteins to damaged DNA. Mutations in FANCB cause a severe, X-linked form of Fanconi anemia, leading to congenital abnormalities, bone marrow failure, cancer predisposition, and infertility, particularly in males[2]. FANCB does not appear to be a direct target for any approved drugs, but its essential role in DNA repair means its dysfunction markedly affects cell survival in response to DNA crosslinking agents[3].
As part of the FA core complex, FANCB enables E3 ubiquitin ligase activity, critical for monoubiquitinating FANCD2 and FANCI, which is a key step in DNA interstrand crosslink repair[1][2][3]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fanconi anemia group B protein (FANCB).